Literature DB >> 11313463

Kinetics of p53 binding to promoter sites in vivo.

S T Szak1, D Mays, J A Pietenpol.   

Abstract

Downstream target genes of p53 are thought to mediate its tumor-suppressive activity, but it is unknown whether differential transactivation of these genes is regulated at the level of p53 binding to their promoters. To address this issue, p53 binding in vivo to consensus sites in the p21(Waf1), MDM2, and PIG3 promoters was investigated in cells exposed to adriamycin (ADR) or ionizing radiation as well as in an inducible p53 cell line. p53-DNA complexes were cross-linked in vivo by treating the cells with formaldehyde and processed by chromatin immunoprecipitation-PCR. This methodology allowed for the analysis of relevant p53-DNA complexes by preventing redistribution of cellular components upon collection of cell extracts. Increased p53 binding to the p21(Waf1), MDM2, and PIG3 promoters occurred within 2 h after p53 activation; however, significant increases in PIG3 transcription did not occur until 15 h after p53 binding. Gel shift analyses indicated that p53 had lower affinity for the consensus binding site in the PIG3 promoters compared to its consensus sites in the p21 and MDM2 genes, which suggests that additional factors may be required to stabilize the interaction of p53 with the PIG3 promoter. Further, acetylated p53 (Lys382) was found in chemically cross-linked complexes at all promoter sites examined after treatment of cells with ADR. In summary, the kinetics of p53 binding in vivo to target gene regulatory regions does not uniformly correlate with target gene mRNA expression for the p53 target genes examined. Our results suggest that target genes with low-affinity p53 binding sites may require additional events and will have delayed kinetics of induction compared to those with high-affinity binding sites.

Entities:  

Mesh:

Year:  2001        PMID: 11313463      PMCID: PMC100259          DOI: 10.1128/MCB.21.10.3375-3386.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  Recruitment of p300/CBP in p53-dependent signal pathways.

Authors:  M L Avantaggiati; V Ogryzko; K Gardner; A Giordano; A S Levine; K Kelly
Journal:  Cell       Date:  1997-06-27       Impact factor: 41.582

2.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

3.  Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit.

Authors:  Y Gu; C W Turck; D O Morgan
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

4.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

5.  Hyperphosphorylation of p53 induced by okadaic acid attenuates its transcriptional activation function.

Authors:  W Zhang; C McClain; J P Gau; X Y Guo; A B Deisseroth
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

6.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

7.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

Authors:  W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

8.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

9.  p53 phosphorylation mutants retain transcription activity.

Authors:  B Fuchs; D O'Connor; L Fallis; K H Scheidtmann; X Lu
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

10.  mdm2 expression is induced by wild type p53 activity.

Authors:  Y Barak; T Juven; R Haffner; M Oren
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

View more
  70 in total

1.  Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.

Authors:  M D Kaeser; R D Iggo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

2.  Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.

Authors:  Eun-Taex Oh; Moon-Taek Park; Bo-Hwa Choi; Seonggu Ro; Eun-Kyung Choi; Seong-Yun Jeong; Heon Joo Park
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

3.  p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage.

Authors:  Carlos P Rubbi; Jo Milner
Journal:  EMBO J       Date:  2003-02-17       Impact factor: 11.598

4.  Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.

Authors:  Michael A Resnick; Alberto Inga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

5.  MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.

Authors:  Lynn Biderman; Masha V Poyurovsky; Yael Assia; James L Manley; Carol Prives
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

6.  Gene-specific repression of the p53 target gene PUMA via intragenic CTCF-Cohesin binding.

Authors:  Nathan P Gomes; Joaquín M Espinosa
Journal:  Genes Dev       Date:  2010-05-15       Impact factor: 11.361

7.  The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations.

Authors:  Matthew D Westfall; Deborah J Mays; Joseph C Sniezek; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  Immobilization of Escherichia coli RNA polymerase and location of binding sites by use of chromatin immunoprecipitation and microarrays.

Authors:  Christopher D Herring; Marni Raffaelle; Timothy E Allen; Elenita I Kanin; Robert Landick; Aseem Z Ansari; Bernhard Ø Palsson
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

9.  Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.

Authors:  Amjad Ali; Muhammad Zeeshan Bhatti; Abdus Saboor Shah; Hong-Quan Duong; Huda Mohammad Alkreathy; Shah Faisal Mohammad; Rahmat Ali Khan; Ayaz Ahmad
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

10.  STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.

Authors:  Geqiang Li; Kristy L Miskimen; Zhengqi Wang; Xiu Yan Xie; Jennifer Brenzovich; John J Ryan; William Tse; Richard Moriggl; Kevin D Bunting
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.